Michael Schmohl

997 total citations
18 papers, 710 citations indexed

About

Michael Schmohl is a scholar working on Cardiology and Cardiovascular Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Michael Schmohl has authored 18 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 6 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Michael Schmohl's work include Atrial Fibrillation Management and Outcomes (8 papers), interferon and immune responses (5 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Michael Schmohl is often cited by papers focused on Atrial Fibrillation Management and Outcomes (8 papers), interferon and immune responses (5 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Michael Schmohl collaborates with scholars based in Germany, United States and United Kingdom. Michael Schmohl's co-authors include Joachim Stangier, Viktoria Moschetti, Paul Reilly, Stephan Glund, Benjamin Lang, Stephen H. Norris, Steven Ramael, Joanne van Ryn, Dietmar Ganßer and Jörg Kreuzer and has published in prestigious journals such as The Lancet, Circulation and Blood.

In The Last Decade

Michael Schmohl

18 papers receiving 686 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Schmohl Germany 11 563 400 73 67 61 18 710
Pritesh Bodalia United Kingdom 6 462 0.8× 217 0.5× 38 0.5× 97 1.4× 27 0.4× 7 616
Maria I. Aguilar United States 12 296 0.5× 123 0.3× 82 1.1× 320 4.8× 36 0.6× 19 742
Yongjun Wang China 9 220 0.4× 66 0.2× 51 0.7× 170 2.5× 4 0.1× 13 381
D.S. Cannom United States 4 1.3k 2.3× 216 0.5× 99 1.4× 123 1.8× 8 0.1× 8 1.4k
A.Allen Seals United States 13 725 1.3× 135 0.3× 259 3.5× 72 1.1× 37 0.6× 18 872
William M. Byra United States 9 430 0.8× 94 0.2× 57 0.8× 57 0.9× 14 0.2× 16 510
Kazuyoshi Suenari Japan 22 1.4k 2.5× 98 0.2× 99 1.4× 67 1.0× 8 0.1× 76 1.5k
Thuy Nguyen Netherlands 9 44 0.1× 99 0.2× 58 0.8× 272 4.1× 14 0.2× 19 451
Jonathan W. Dukes United States 12 545 1.0× 25 0.1× 141 1.9× 62 0.9× 16 0.3× 31 738
Hercules E. Mavrakis Greece 17 1.5k 2.6× 68 0.2× 90 1.2× 19 0.3× 10 0.2× 41 1.6k

Countries citing papers authored by Michael Schmohl

Since Specialization
Citations

This map shows the geographic impact of Michael Schmohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schmohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schmohl more than expected).

Fields of papers citing papers by Michael Schmohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schmohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schmohl. The network helps show where Michael Schmohl may publish in the future.

Co-authorship network of co-authors of Michael Schmohl

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schmohl. A scholar is included among the top collaborators of Michael Schmohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schmohl. Michael Schmohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Harrington, Kevin J., Shigehisa Kitano, Valentina Gambardella, et al.. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncology. 21(2). 195–200. 2 indexed citations
2.
Calvo, Emiliano, Elena Garralda, Guzmán Alonso, et al.. (2023). 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Annals of Oncology. 34. S626–S626. 7 indexed citations
3.
Harrington, Kevin J., Elizabeth M. Dowling, Robert Latek, Michael Schmohl, & Patricia LoRusso. (2022). 626 Trial in progress: an intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab. Regular and Young Investigator Award Abstracts. A658–A658. 2 indexed citations
4.
Harrington, Kevin J., Eileen E. Parkes, Jared Weiss, et al.. (2021). Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors. Cancer Research. 81(13_Supplement). CT217–CT217. 8 indexed citations
5.
Harrington, Kevin J., Eileen E. Parkes, Jared Weiss, et al.. (2020). 408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors. Regular and Young Investigator Award Abstracts. A248.1–A248. 4 indexed citations
6.
Yasaka, Masahiro, Ippei Ikushima, Akiko Harada, et al.. (2017). Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Research and Practice in Thrombosis and Haemostasis. 1(2). 202–215. 13 indexed citations
7.
Schmohl, Michael, Stephan Glund, Akiko Harada, et al.. (2016). Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thrombosis and Haemostasis. 117(2). 269–276. 23 indexed citations
8.
Glund, Stephan, Joachim Stangier, Joanne van Ryn, et al.. (2016). Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clinical Pharmacokinetics. 56(1). 41–54. 58 indexed citations
9.
Schmohl, Michael, Dietmar Ganßer, Viktoria Moschetti, & Joachim Stangier. (2015). Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thrombosis Research. 135(3). 532–536. 11 indexed citations
10.
Moschetti, Viktoria, Stephen H. Norris, Joachim Stangier, et al.. (2015). A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thrombosis and Haemostasis. 113(5). 943–951. 183 indexed citations
11.
12.
Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2014). Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood. 124(21). 344–344. 59 indexed citations
13.
Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2013). Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation. 128. 41 indexed citations
14.
Laske, Christoph, Michael Schmohl, Thomas Leyhe, et al.. (2013). Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients. Journal of Alzheimer s Disease. 34(2). 367–375. 16 indexed citations
15.
Schmohl, Michael, et al.. (2012). Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood. International Immunopharmacology. 14(4). 722–728. 11 indexed citations
16.
Schmohl, Michael, Stefan Beckert, Thomas Joos, et al.. (2012). Superficial Wound Swabbing. Diabetes Care. 35(11). 2113–2120. 27 indexed citations
17.
Schmohl, Michael, et al.. (2011). Functional Analysis of Rho GTPase Activation and Inhibition in a Bead-Based Miniaturized Format. Methods in molecular biology. 827. 271–282. 2 indexed citations
18.
Schmohl, Michael, Oliver Pötz, Yoel Kloog, et al.. (2010). Protein–protein‐interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition. PROTEOMICS. 10(8). 1716–1720. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pritesh Bodalia Breakdown of academic impact, for papers by Maria I. Aguilar Breakdown of academic impact, for papers by Yongjun Wang Breakdown of academic impact, for papers by D.S. Cannom Breakdown of academic impact, for papers by A.Allen Seals Breakdown of academic impact, for papers by William M. Byra Breakdown of academic impact, for papers by Kazuyoshi Suenari Breakdown of academic impact, for papers by Thuy Nguyen Breakdown of academic impact, for papers by Jonathan W. Dukes Breakdown of academic impact, for papers by Hercules E. Mavrakis
Rankless by CCL
2026